Home / Products / Genome-edited Cells / CAV1 Knockout A-549 Cell Line

CAV1 Knockout A-549 Cell Line

Cat. No. ARG0076
Product Type:

Genome-edited Cells

Tissue Source:

Lung

In stock
Request a Quote

Short Description 🔒

CAV1 Knockout A-549 is a human CRISPR/Cas9-edited alveolar epithelial adenocarcinoma cell line with disruption of the caveolin-1 gene. In the lung-derived A-549 background, this model supports analysis of caveolae biology, membrane trafficking, and signaling pathways regulated by CAV1, including EGFR, SRC-PTK2/FAK, PI3K-AKT, MAPK-ERK, mechanotransduction, and cholesterol homeostasis. Loss of CAV1 provides a useful system for studying epithelial adhesion, migration, endocytosis, and treatment response in lung cancer-relevant contexts using western blotting, phospho-signaling assays, microscopy, RNA-seq, cholesterol transport assays, and migration or invasion assays.

Product Details
Cell Engineering
Immortalization
Culture Conditions
Quality Control
Disclaimer

Product Details

Product Type:
Genome-edited Cells
Tissue Source:
Lung
Disease:
Carcinoma
Morphology:
Epithelial-like
Age:
58 years
Sex of Donor:
Male
Size/Quantity:
1 million
Shipping info:
Cryopreserved in vials and shipped on dry ice

Cell Engineering Information

Host Cell:
A-549
Gene Name:
CAV1
Gene Identifier:
NCBI Gene ID 857
Gene Species:
Homo sapiens (Human)

Immortalization Information

No immortalization information available.

Culture Conditions

Temperature:
37°C
Atmosphere:
5% CO₂

Quality Control

Mycoplasma testing:
Negative for mycoplasma through PCR analysis
Sterility testing:
Daily monitoring confirms that the cells are free from bacterial, yeast, and fungal contamination.
Pathogens:
Cells tested negative for HIV-1, HBV, and HCV.

Disclaimer

Intended Use:
This product is intended for laboratory in vitro use only. It is not intended for diagnostic, therapeutic, or clinical applications.
Disclaimer:
Ascent Research endeavors to provide accurate and up-to-date product information. However, no warranties or representations are made regarding its completeness or reliability.
Usage:
By accepting this product, the customer acknowledges and agrees to assume all risks associated with its receipt, handling, storage, disposal, and use. This product is provided "AS IS".

Description 🔒

The CAV1 Knockout A-549 Cell Line is a human CRISPR/Cas9-engineered cell model in which the CAV1 gene has been disrupted to eliminate functional caveolin-1 expression. This stable edited line is generated in A-549 cells, a human alveolar basal epithelial adenocarcinoma background, and provides an in vitro system for investigating caveolae-associated membrane organization, receptor signaling, and epithelial response programs in a lung-derived context.

A-549 cells are widely used as a pulmonary epithelial model because they retain alveolar type II-like features and support studies of epithelial barrier biology, lung cancer signaling, membrane trafficking, and pharmacologic response. As a human lung adenocarcinoma cell line, A-549 is relevant to research on tumor progression, epithelial plasticity, growth-factor signaling, and host response pathways. Its established use in imaging, biochemical signaling assays, and functional perturbation studies makes it a practical host background for defining how specific gene loss alters pulmonary epithelial behavior.

CAV1 encodes caveolin-1, a principal structural component of caveolae that forms membrane-associated complexes with factors including CAVIN1/PTRF, EHD2, EGFR, SRC, PTK2/FAK, ITGB1, NOS3, and filamin A. Caveolin-1 organizes lipid raft and caveolar microdomains and modulates signaling downstream of integrin engagement, EGF stimulation, TGF-beta1, mechanical stress, hypoxia, and altered cholesterol availability. Through these interactions, CAV1 regulates caveolae-mediated endocytosis, cholesterol trafficking, and mechanotransduction, while influencing SRC phosphorylation state, FAK/PTK2 signaling, AKT1 activation, MAPK1/MAPK3-driven ERK1/2 signaling, RHOA activity, CDH1-associated adhesion dynamics, and migratory behavior. Because these signaling axes are strongly linked to lung cancer, fibrosis-associated remodeling, and vascular or metabolic dysfunction, CAV1 loss is a useful perturbation for pathway-level studies.

In the A-549 background, knockout of CAV1 enables direct analysis of how caveolar disruption reprograms epithelial membrane architecture and signaling output in a lung cancer-relevant system. This model is particularly informative for examining dependencies between caveolae integrity and EGFR, PI3K-AKT, MAPK-ERK, integrin-SRC-FAK, or TGF-beta pathway activity, as well as the effects of altered cholesterol distribution on adhesion, motility, and growth control.

Researchers can apply this cell line in western blotting and phospho-signaling studies to assess SRC, FAK, AKT1, or ERK1/2 pathway responses; in RT-qPCR or RNA-seq to profile gene-expression changes following growth-factor, hypoxic, or mechanical perturbation; and in immunofluorescence or confocal microscopy to examine caveolae markers, membrane organization, and cytoskeletal remodeling. The model is also suited for co-immunoprecipitation of caveolar signaling complexes, cholesterol uptake or efflux assays, endocytosis measurements, migration and invasion assays, proliferation and apoptosis studies, and drug sensitivity testing in lung cancer and membrane-trafficking research workflows. Researchers may contact Ascent Research for additional technical information, product details, or related gene-edited cell models.